Processa Pharmaceuticals, Inc. current report, 16 February 2015

Business Context and Reporting Period

This Form 8-K was filed by Heatwurx, Inc. (not Processa Pharmaceuticals, Inc.) on February 20, 2015, reporting events occurring on February 16, 2015. The company is a Delaware corporation headquartered in Gardena, California.

Key Financial Metrics and Obligations

  • Debt Facility: Entered into a Senior Secured Loan Agreement with JMW Fund, LLC, Richland Fund, LLC, and San Gabriel Fund, LLC.
  • Total Commitment: Up to $2,000,000 aggregate loan amount.
  • Initial Drawdown: $90,000 funded via Promissory Notes on February 16, 2015.
  • Interest Rate: 12% per annum, payable monthly starting March 1, 2015.
  • Maturity Date: August 16, 2015.
  • Collateral: Secured by all assets of the Company and its subsidiaries, including intellectual property rights.
  • Guarantors: Dr. Pave, LLC and Dr. Pave Worldwide, LLC.

Material Changes

The filing discloses the creation of a new direct financial obligation. The company has moved from an unspecified prior debt position to a secured debt facility with a $2,000,000 cap, with an immediate liability of $90,000. The filing does not provide comparative financial data for the prior period.

Outlook, Risks, and Contingencies

  • Default Penalties: If interest payments remain unpaid for more than 90 days, the interest rate on the overdue amount increases to 18% per annum.
  • Acceleration: Default on principal or interest triggers acceleration of the Notes.
  • Foreclosure Risk: Upon an Event of Default, Lenders have the right to foreclose on all Company assets.
  • Liquidity: The filing does not provide specific cash flow or liquidity metrics beyond the new debt obligation.

Investor Verification Checklist

  • Verify the company name discrepancy (Filing lists Heatwurx, Inc.; request metadata listed Processa Pharmaceuticals, Inc.).
  • Confirm the company's ability to service the 12% interest payments starting March 1, 2015.
  • Assess the impact of the security interest on all assets, including intellectual property, on future financing or operations.
  • Review the financial health of the guarantors (Dr. Pave, LLC and Dr. Pave Worldwide, LLC).
  • Determine if the company intends to draw the remaining $1,910,000 of the committed facility.